News from janssen pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 13, 2011, 08:38 ET
Dec 12, 2011, 13:00 ET

Bahnbrechende VISTA-studie zeigt signifikante verbesserungen in der langzeit-gesamtüberlebensrate bei der therapie von bisher unbehandeltem multiplem myelom mit VELCADE® (bortezomib)

Die Vorteile von Bortezomib in Kombination mit Melphalan und Prednison (VMP) wurden bei zahlreichen Patientensubgruppen unabhängig von der...

Dec 12, 2011, 13:00 ET

L' importante studio VISTA ha dimostrato un vantaggio significativo di sopravvivenza a lungo termine in pazienti con mieloma multiplo di nuova diagnosi trattati con VELCADE(R) (bortezomib)

I benefici di bortezomib, associato a melphalan e a prednisone (VMP) sono stati osservati  in diversi sottogruppi di pazienti...

Dec 12, 2011, 13:00 ET
Dec 09, 2011, 06:14 ET

L'efficacité de VELCADE soutenue par de nouvelles donnees presentees lors du 53eme Congres Annuel de la Societe Americaine d'hematologie

Les donnés de suivi à cinq ans recueillies au cours d'une étude pivot portant sur l'utilisation de...

Dec 09, 2011, 03:00 ET

53.Jahrestagung der American Society of Hematology: Wachsende Evidenzgrundlage für VELCADE

Bahnbrechende 5-Jahres Nachbeobachtungsdaten zu VELCADE®  (Bortezomib) bei Patienten mit zuvor unbehandeltem multiplen Myelom...

Dec 09, 2011, 03:00 ET

Se construye la base de evidencias de VELCADE al tiempo que se presentan nuevos datos

- Se construye la base de evidencias de VELCADE al tiempo que se presentan nuevos datos en la 53 reunión anual de la American Society of...

Dec 08, 2011, 16:21 ET

Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765

 Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed...

Nov 10, 2011, 14:00 ET

Janssen Pharmaceutical Companies Launch Healthy Minds Initiative to Spur Neuroscience Collaboration and Support Millions Suffering from Brain Disorders

Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") today announced the launch of Healthy Minds, a comprehensive initiative to...

Nov 04, 2011, 13:43 ET

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke...

Oct 31, 2011, 08:00 ET

Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a supplemental New...

Sep 14, 2011, 09:00 ET
Janssen Pharmaceuticals, Inc. logo.  (PRNewsFoto/Janssen Pharmaceuticals, Inc.)

New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults

A new survey shows almost half (44%) of U.S. patients in outpatient settings received potentially inadequate relief of moderate-to-severe acute...

Aug 26, 2011, 08:30 ET

NUCYNTA® ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain

Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved NUCYNTA® ER, an oral analgesic taken...

Aug 16, 2011, 09:00 ET
PrescribeResponsibly.com logo.  (PRNewsFoto/Janssen Pharmaceuticals, Inc.)

Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com

New Offerings Provide Physicians with Resources for Safe, Appropriate Pain Management To assist healthcare professionals in managing their...

Jul 15, 2011, 08:43 ET

Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division

Janssen Pharmaceuticals, Inc. today announced a definitive agreement to divest the assets of its Ortho Dermatologics division in the U.S. to...

Jul 01, 2011, 17:23 ET

Multimedia: FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery

Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets),...

Jul 01, 2011, 15:00 ET

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery

Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets),...

Jun 17, 2011, 13:36 ET

Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. is initiating a voluntary recall of one lot of RISPERDAL® (risperidone) 3mg Tablets, marketed by...

May 09, 2011, 08:00 ET

"Living with Schizophrenia" Documentary Shines Spotlight on People with Schizophrenia: A Misunderstood and Stigmatized Illness

Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., proudly announces the world premiere of "Living with Schizophrenia: A Call for...

Apr 14, 2011, 08:48 ET

Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX®

Ortho-McNeil Neurologics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., today announced it is voluntarily recalling two lots of...